Q/C Technologies (QCLS) Q2 2025 earnings summary

Executive summary

• Net loss attributable to stockholders was $4.7 million for the six months ended June 30, 2025, with no product revenue generated during the period.

• Cash on hand was $207,553 and marketable securities were $3.6 million as of June 30, 2025.

• The company is advancing clinical programs for Isomyosamine and Supera-CBD, including a Phase 2b trial and AI-driven patient identification initiatives.

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

• Recent amendments extended the maturity dates of Series F and F-1 Preferred Stock to December 31, 2025, and modified warrant terms.

Financial highlights

• Operating expenses for the six months ended June 30, 2025, were $4.3 million, down from $6.2 million year-over-year.

• Research and development expenses increased to $2.4 million from $1.6 million year-over-year, driven by Phase 2B study costs.

• General and administrative expenses decreased to $1.7 million from $2.1 million year-over-year, reflecting staff reductions.

• Net loss for the six months ended June 30, 2025, was $2.9 million, a significant improvement from $19.4 million in the prior year period.

• Stock-based compensation expense was $189,490 for the six months ended June 30, 2025.

Outlook and guidance

• The company anticipates increased expenses as it advances clinical development and commercialization efforts for Isomyosamine and Supera-CBD.

• Additional capital will be required to support ongoing operations and growth strategy.

• Management is evaluating the impact of the 2025 Taxpayer Fairness and Growth Act, which may affect future tax rates and deferred tax balances.